NASDAQ : TKNO
Alpha Teknova, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 8.09 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 499.17M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 454.13M |
| Enterprise Value | 464.10M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 61.70M |
| Shares Outstanding | 61.70M |
| Shares Change (YoY) | +0.99% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 8.07% |
| Owned by Institutions (%) | 14.93% |
| Float | 19.00M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.39 |
| Forward PS | 9.31 |
| PB Ratio | 6.31 |
| P/TBV Ratio | 8.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 10.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.49 |
| Quick Ratio | 3.32 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.56 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -24.19% |
| Return on Assets (ROA) | -9.28% |
| Return on Invested Capital (ROIC) | -20.76% |
| Return on Capital Employed (ROCE) | -17.21% |
| Weighted Average Cost of Capital (WACC) | 8.60% |
| Revenue Per Employee | $276,582 |
| Profits Per Employee | -$106,133 |
| Employee Count | 158 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 3.94 |
Taxes
| Measure | Value |
|---|
| Income Tax | 94,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.86 |
| 52-Week Price Change | +36.80% |
| 50-Day Moving Average | 7.71 |
| 200-Day Moving Average | 4.89 |
| Relative Strength Index (RSI) | 48.10 |
| Average Volume (20 Days) | 752,950 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.65M |
| Short Previous Month | 1.63M |
| Short % of Shares Out | 2.67% |
| Short % of Float | 8.68% |
| Short Ratio (days to cover) | 5.37 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 43.70M |
| Gross Profit | 15.12M |
| Operating Income | -15.31M |
| Pretax Income | -16.68M |
| Net Income | -16.77M |
| EBITDA | -8.97M |
| EBIT | -15.31M |
| Loss Per Share | -$0.31 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 17.44M |
| Total Debt | 27.41M |
| Net Cash | -9.97M |
| Net Cash Per Share | -$0.16 |
| Equity (Book Value) | 62.60M |
| Book Value Per Share | 1.17 |
| Working Capital | 23.95M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -6.27M |
| Capital Expenditures | -1.08M |
| Depreciation & Amortization | 6.34M |
| Net Borrowing | n/a |
| Free Cash Flow | -7.35M |
| FCF Per Share | -$0.12 |
Margins
| Measure | Value |
|---|
| Gross Margin | 34.60% |
| Operating Margin | -35.04% |
| Pretax Margin | -38.16% |
| Profit Margin | -38.37% |
| EBITDA Margin | -20.53% |
| EBIT Margin | -35.04% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.99% |
| Shareholder Yield | -0.99% |
| Earnings Yield | -4.25% |
| FCF Yield | -1.62% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.67 |
| Price Target Difference | 31.35% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 15.39% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.09 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |